| 000 | 01471 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513002029.0 | ||
| 264 | 0 | _c19830119 | |
| 008 | 198301s 0 0 eng d | ||
| 022 | _a0098-1532 | ||
| 024 | 7 |
_a10.1002/mpo.2950100503 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRivera, G | |
| 245 | 0 | 0 |
_aVM-26 with prednisone and vincristine for treatment of refractory acute lymphocytic leukemia. _h[electronic resource] |
| 260 |
_bMedical and pediatric oncology _c1982 |
||
| 300 |
_a439-46 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Lymphoid _xdrug therapy |
| 650 | 0 | 4 |
_aPodophyllotoxin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aTeniposide _xadministration & dosage |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aBowman, W P | |
| 700 | 1 | _aMurphy, S B | |
| 700 | 1 | _aDahl, G V | |
| 700 | 1 | _aAur, R J | |
| 700 | 1 | _aKalwinsky, D K | |
| 700 | 1 | _aWood, A | |
| 700 | 1 | _aStagner, S | |
| 700 | 1 | _aAvery, T L | |
| 773 | 0 |
_tMedical and pediatric oncology _gvol. 10 _gno. 5 _gp. 439-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/mpo.2950100503 _zAvailable from publisher's website |
| 999 |
_c6958635 _d6958635 |
||